https://www.ema.europa.eu/en/medicines/human/EPAR/exblifep
Orchid Pharma’s ‘Exblifep’ received positive recommendation from EMA.
The drug is cefepime+enmetazobactam, indicated for uses in
- Complicated urinary tract infections (cUTI), including pyelonephritis
- Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)
Can there be an impact on WCK 5222’s market size, given that one of the uses for this drug can be for Hospital acquired infections like VAP?
| Subscribe To Our Free Newsletter |
